drugset
drugset / Trial / NCT07160400

A Study of IBI3032 in Chinese Healthy Participants and Participants With Overweight or Obesity

NCT07160400 ↗

Phase 1 Recruiting 104 enrolled Innovent Biologics Technology Limited (Shanghai R&D Center)
RandomizedSequentialDouble-blindTreatment

Summary

This is a randomized, double-blind, placebo-controlled phase 1 clinical study evaluating the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of a single ascending dose of IBI3032 in healthy participants and multiple ascending doses of IBI3032 in participants with overweight or obesity. It consists of 2 parts: Part A is a single ascending dose (SAD) study in healthy participants, and Part B is a multiple ascending dose (MAD) study in participants with overweight or obesity during the 4-week treatment period.

Timeline

Start
2025-09-04
Primary completion
2026-05-29
Completion
2026-09-30

Drugs

EvaluationDrugModalityDoseRoute
Subject IBI3032 Unknown — Oral

Indications

No indication recorded.